Evotec SE (EVO) Non-Current Assets (2009 - 2026)
Evotec SE (EVO) posted Non-Current Assets of $1.1 million for Q1 2026, down 1.8% sequentially from $1.1 million in Q4 2025, and down 15.36% YoY from $1.3 million in Q1 2025.
Evotec SE (EVO) Non-Current Assets (2009 - 2026) Analysis & Trends
Evotec SE has reported Non-Current Assets for 9 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 15.36% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 15.36% YoY) and the FY2025 annual result came in at $1.1 million, down 99.91% from the prior year.
- Non-Current Assets retreated to $1.1 million in Q1 2026 per EVO's latest filing, from $1.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.3 billion in Q4 2023 and troughed at $1.1 million in Q1 2026.
- A 5-year average of $302.6 million and a median of $1.3 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets grew 21.02% in 2023, then slumped 99.91% in 2025.
- Over 5 years, Non-Current Assets stood at $1.1 billion in 2022, then grew by 21.02% to $1.3 billion in 2023, then declined by 1.37% to $1.3 billion in 2024, then sank by 99.91% to $1.1 million in 2025, then decreased by 1.8% to $1.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.27 Bn |
| Sep 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 1.29 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Sep 30, 2022 | 1.18 Mn |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 970.17 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Dec 31, 2020 | 898.44 Mn |
| Sep 30, 2010 | 125,722.18 |
| Jun 30, 2010 | 90,917.59 |
| Mar 31, 2010 | 108.58 |
| Dec 31, 2009 | 114,656.60 |
| Jun 30, 2009 | 114.84 Mn |